Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Clinical trial NCT06994845 · RECRUITING

Trial details

NCT number: NCT06994845
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Immunoglobulin A Nephropathy (IgAN)

Start date: 2025-11-27
Primary completion: 2030-06-28
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.